REDCARE PHARMACY NV (RDC.DE) Stock Earnings & Estimates
Europe - FRA:RDC - NL0012044747 - Common Stock
87.05 EUR
-0.65 (-0.74%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.204B 13.59% | 1.799B 49.35% | 2.371B 31.79% | 3.016B 27.23% | 3.616B 19.89% | 4.269B 18.06% | 4.812B 12.72% | 5.649B 17.39% | 5.903B 4.50% | 6.372B 7.95% | 6.725B 5.54% | |
| EBITDA YoY % growth | -13.99M 64.07% | 49.669M 455.03% | 29.778M -40.05% | 64.096M 115.25% | 119.16M 85.91% | 179.9M 50.97% | 281.18M 56.30% | 365.12M 29.85% | N/A | N/A | N/A | |
| EBIT YoY % growth | -53.5M 18.82% | -7.619M 85.76% | -38.439M -404.52% | -12.443M 67.63% | 45.307M 464.12% | 88.86M 96.13% | 209.46M 135.72% | 229.94M 9.78% | 265.93M 15.65% | N/A | N/A | |
| Operating Margin | -4.44% | -0.42% | -1.62% | -0.41% | 1.25% | 2.08% | 4.35% | 4.07% | 4.50% | N/A | N/A | |
| EPS YoY % growth | N/A -46.28% | N/A 74.56% | N/A -91.90% | -0.97 49.41% | 0.83 184.67% | 2.90 252.07% | 7.60 161.62% | 12.02 58.14% | N/A | N/A | N/A |
All data in EUR
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.32 8.81% | -0.84 36.49% |
| Revenue Q2Q % growth | 733.09M 27.59% | 841.87M 24.70% |
| EBITDA Q2Q % growth | 16.362M -62.80% | 25.351M -43.62% |
| EBIT Q2Q % growth | 100.00% | N/A |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 0.46 319.05% | -0.22 | 0.68 | 313.82% |
| Q1 2025 Q2Q % growth | -0.53 | -0.72 | 0.19 | 26.81% |
| Q4 2024 Q2Q % growth | -1.32 | -0.93 | -0.39 | -42.68% |
| Q3 2024 Q2Q % growth | -0.35 | -0.66 | 0.31 | 47.25% |
| Q2 2024 Q2Q % growth | -0.21 | -0.08 | -0.13 | -159.90% |
| Q4 2021 Q2Q % growth | -2.46 | -1.29 | -1.17 | -90.28% |
| Q3 2021 Q2Q % growth | -0.79 | -0.49 | -0.30 | -59.63% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 709.189M 26.49% | 717.28M | -8.091M | -1.13% |
| Q1 2025 Q2Q % growth | 717.286M 28.04% | 722.84M | -5.554M | -0.77% |
| Q4 2024 Q2Q % growth | 675.137M 27.07% | 690.64M | -15.503M | -2.24% |
| Q3 2024 Q2Q % growth | 574.548M 20.83% | 581.98M | -7.432M | -1.28% |
| Q2 2024 Q2Q % growth | 560.674M 33.53% | 380.37M | 180.304M | 47.40% |
| Q1 2024 Q2Q % growth | 560.216M 50.56% | % | ||
| Q4 2023 Q2Q % growth | 531.318M 62.09% | % | ||
| Q3 2023 Q2Q % growth | 475.5M 67.14% | % | ||
| Q2 2023 Q2Q % growth | 419.9M 46.20% | % | ||
| Q1 2023 Q2Q % growth | 372.1M 22.08% | % | ||
| Q4 2022 Q2Q % growth | 327.8M 13.82% | % | ||
| Q3 2022 Q2Q % growth | 284.5M 19.59% | % | ||
| Q2 2022 Q2Q % growth | 287.2M 14.70% | % | ||
| Q1 2022 Q2Q % growth | 304.8M 7.29% | % | ||
| Q4 2021 Q2Q % growth | 288M 8.80% | 293.18M | -5.18M | -1.77% |
| Q3 2021 Q2Q % growth | 237.9M -0.34% | 248.93M | -11.03M | -4.43% |
| Q2 2021 Q2Q % growth | 250.4M 7.61% | % | ||
| Q1 2021 Q2Q % growth | 284.1M 22.46% | % | ||
| Q4 2020 Q2Q % growth | 264.7M 37.94% | % | ||
| Q3 2020 Q2Q % growth | 238.7M 39.67% | % | ||
| Q2 2020 Q2Q % growth | 232.7M 42.24% | % | ||
| Q1 2020 Q2Q % growth | 232M 32.88% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -28.98% | 2.84% | 11.46% |
| Revenue | 0% | -0.24% | 0% | 0.13% |